Lamm W - Search Results

1

Expression levels of Akt in nimesulide-treated squamous carcinoma cell lines of the head and neck.

Vormittag L, Lamm W, Erovic BM, Czembirek C, Kornek G, Thurnher D. Vormittag L, et al. Among authors: lamm w. Oncol Rep. 2005 Feb;13(2):207-10. Oncol Rep. 2005. PMID: 15643499

2

The effect of nimesulide, a selective cyclooxygenase-2 inhibitor, on Ets-1 and Ets-2 expression in head and neck cancer cell lines.

Lamm W, Vormittag L, Turhani D, Erovic BM, Czembirek C, Eder-Czembirek C, Thurnher D. Lamm W, et al. Head Neck. 2005 Dec;27(12):1068-72. doi: 10.1002/hed.20285. Head Neck. 2005. PMID: 16240325

3

Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition.

Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E, Czerwenka K. Singer CF, et al. Among authors: lamm w. Oncol Rep. 2006 Feb;15(2):353-9. Oncol Rep. 2006. PMID: 16391854

4

Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.

Vogl UM, Berger W, Micksche M, Pirker C, Lamm W, Pichelmeyer O, Zielinski CC, Schmidinger M. Vogl UM, et al. Among authors: lamm w. Cancer Lett. 2009 May 18;277(2):218-26. doi: 10.1016/j.canlet.2008.12.013. Epub 2009 Jan 25. Cancer Lett. 2009. PMID: 19171421

5

Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab.

Prager GW, Lackner EM, Krauth MT, Unseld M, Poettler M, Laffer S, Cerny-Reiterer S, Lamm W, Kornek GV, Binder BR, Zielinski CC, Valent P. Prager GW, et al. Among authors: lamm w. Mol Oncol. 2010 Apr;4(2):150-60. doi: 10.1016/j.molonc.2010.01.002. Epub 2010 Jan 7. Mol Oncol. 2010. PMID: 20106729 Free PMC article.

6

Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma.

Lamm W, Amann G, Brodowicz T. Lamm W, et al. Case Rep Oncol. 2010 Sep;3(3):477-9. doi: 10.1159/000323261. Epub 2010 Dec 15. Case Rep Oncol. 2010. PMID: 21611101 Free PMC article.

7

Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors.

Singer CF, Hudelist G, Lamm W, Mueller R, Czerwenka K, Kubista E. Singer CF, et al. Among authors: lamm w. Endocr Relat Cancer. 2004 Dec;11(4):861-9. doi: 10.1677/erc.1.00801. Endocr Relat Cancer. 2004. PMID: 15613459

8

Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.

Lamm W, Vogl UM, Bojic M, Zielinski C, Klingler C, Kramer G, Schmidinger M. Lamm W, et al. Acta Oncol. 2012 Jan;51(1):101-6. doi: 10.3109/0284186X.2011.589404. Epub 2011 Jul 8. Acta Oncol. 2012. PMID: 21736504

9

Bortezomib administered subcutaneously is well tolerated in bortezomib-based combination regimens used in patients with multiple myeloma.

Lamm W, Drach-Schauer B, Eder S, Drach J. Lamm W, et al. Oncology. 2013;85(4):223-7. doi: 10.1159/000355197. Epub 2013 Sep 27. Oncology. 2013. PMID: 24080991

10

Clinical signs of neurofibromatosis impact on the outcome of malignant peripheral nerve sheath tumors.

Lamm W, Schur S, Köstler WJ, Funovics P, Windhager R, Amann G, Panotopoulos J, Pokrajac B, Brodowicz T. Lamm W, et al. Oncology. 2014;86(2):122-6. doi: 10.1159/000357137. Epub 2014 Jan 28. Oncology. 2014. PMID: 24480823

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

145 results

Search Page

Filters